• ___
  • Svenska
  • Career
  • Contact
  • Facebook
  • Twitter
  • Linkedin
  • About IRLAB
    • About IRLAB
    • Management
    • Board of directors
  • Therapeutic focus
    • Therapeutic focus
    • Parkinson’s disease
      • Patient portrait
    • PD-LIDs
    • PD-Falls
  • Project portfolio
    • Project portfolio
    • Mesdopetam (IRL790)
    • Pirepemat (IRL752)
    • IRL942
    • IRL757
    • IRL1117
    • Discovery phase
  • Research platform
    • ISP platform
    • Scientific publications
  • Newsroom
    • Newsroom
    • Press releases
    • Image library
  • Investors
    • Investors
    • Capital Markets Day 2023
    • Financial reports
    • Presentations & events
    • The share
      • Owners
      • Share capital development
      • PDMR transactions
      • Analysts
    • Financial calendar
    • CMD 2022
    • Listing Nasdaq Stockholm Main Market 2020
    • Rights issue Feb 2020
    • Initial public offering 2017
    • IR contacts
  • Corporate Governance
    • Corporate Governance
    • General Meetings
      • Annual General Meeting 2024
      • Previous general meetings
    • Corporate governance reports
    • Nomination committee
      • Nomination Committee for the AGM 2025
      • Previous nomination committees
    • Auditor
    • Remuneration
    • Internal control
    • Diversity
    • Articles of association
Hem>Other

SUBSCRIBE

IRLAB THERAPEUTICS AB
ARVID WALLGRENS BACKE 20
413 46 GÖTEBORG, SVERIGE

info@irlab.se
+46(0)31 757 38 00

youtube-filled